WHO prequalifies antiparasitic API

Generics/General | Posted 06/12/2019 post-comment0 Post your comment

The World Health Organization (WHO) has announced the prequalification of Pyrimethamine, manufactured by Macleods Pharmaceuticals Ltd, as an active pharmaceutical ingredient (API).

09 AA008582

WHO announced in October 2019 that pyrimethamine (WHOAPI-371) has been prequalified by the WHO Prequalification Team as an API.

WHO performs prequalification of APIs to assist in the production of high quality medicines. Its process consists of a comprehensive evaluation, including checking the API Master File to assure compliance with WHO standards and assessing manufacturing sites to confirm good manufacturing practice (GMP) standards are being met.

Pyrimethamine is a small molecule drug used to treat parasitic diseases including toxoplasmosis. It is typically given with follinic acid to reduce toxic effects.

Pyrimethamine has been prequalified by WHO for use in finished pharmaceutical products for the treatment of malaria. The prequalified product is produced by India-based Macleods Pharmaceuticals.

Related articles
WHO prequalifies first generic hepatitis C drug

WHO to launch prequalification programme for biosimilars

WHO prequalification programme for APIs

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

Source: World Health Organization

comment icon Comments (0)
Post your comment
Related content
Pharmaceutical manufacturing companies in Brazil
91 AA007225
Generics/General Posted 26/08/2022
Pharmaceutical companies in Argentina
150 AA010692
Generics/General Posted 08/07/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010